No Pharmacokinetic or Pharmacodynamic Interaction Between Theophylline and the Leukotriene Biosynthesis Inhibitor BAY x 1005-Reference-Cited by-同舟云学术

No Pharmacokinetic or Pharmacodynamic Interaction Between Theophylline and the Leukotriene Biosynthesis Inhibitor BAY x 1005

Published:1996-07 Issue:7 Volume:36 Page:639-646
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Groen Henk,Moesker Harm L.,Leeuwenkamp Oscar R.,Sollie Frans A. E.,Jonkman Jan H. G.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference17 articles.

1. Mode of action of the new selective leukotriene synthesis inhibitor BAY × 1005 {(R)-2-[4-quinolin-2-yl-me-thoxy)phenyl]-2-cyclopentyl acetic acid} and structurally related compounds;Hatzelmann;Biochem Pharmacol,1993

2. BAY × 1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics;Müller-Peddinghaus;J Pharmacol Exp Ther,1993

3. In vitro pharmacology of BAY × 1005, a new inhibitor of leukotriene synthesis;Fruchtmann;Agents Actions,1993

4. Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases;Lewis;N Engl J Med,1990

5. Arachidonic acid metabolism: role in inflammation;Samuelsson;Z Rheumatol,1991

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leukotriene modifiers: novel therapeutic opportunities in asthma;Il Farmaco;2002-03

2. The development of BAY X 1005 and the Bayer series of leukotriene biosynthesis inhibitors;Novel Inhibitors of Leukotrienes;1999

3. Clinical Pharmacology of Leukotriene Receptor Antagonists and 5-Lipoxygenase Inhibitors;American Journal of Respiratory and Critical Care Medicine;1998-06